Good Vs. Right Money: Choosing Optimal Financing Avenues For Biotech
This article was originally published in Start Up
Is all capital welcome? Investor attributes matter when raising capital and different attributes matter at different times in the life of a company, says a panel of investors and biotech leaders.
You may also be interested in...
The New Revolutionary: Ovid's Levin On Pioneering In Neurology
Emerging Company Profile: Orphan disease-focused Ovid Therapeutics, with $80m in VC financing in the bag and an alliance with Takeda, recently raised $75m in a US initial public offering. Scrip spoke with CEO Jeremy Levin and chief business and finance officer Yaron Werber before the recent IPO about how the young biotech firm intends to become a successful neurology company.
Restructuring for Success: Shifting Biotech Strategies
During a panel discussion at Elsevier Business Intelligence’s Therapeutic Area Partnerships conference in Boston in December 2011, experienced investors and biotech executives drew lessons from difficult restructurings and successful transitions.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.